


SEASONAL MALARIA CHEMOPREVENTION

WITH SULFADOXINE-
PYRIMETHAMINE PLUS
AMODIAQUINE IN CHILDREN


A FIELD GUIDE



SEASONAL MALARIA CHEMOPREVENTION

WITH SULFADOXINE–
PYRIMETHAMINE PLUS
AMODIAQUINE IN CHILDREN

A FIELD GUIDE
JULY, 2013



WHO Library Cataloguing-in-Publication Data

Seasonal malaria chemoprevention with sulfadoxine–pyrimethamine plus amodiaquine in children: a field guide.

1.Malaria – prevention and control. 2.Antimalarials – therapeutic use. 3.Chemoprevention – methods. 4.Pyrimethamine – therapeutic use. 5.Sulfadoxine – therapeutic use. 6.Child. 7.Infant. 8.Seasons. 9.Practice guideline. I. World Health Organization. Global Malaria Programme.

ISBN 978 92 4 150473 7

(NLM classification: QV 256)

© World Health Organization 2013

All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int).

Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Design & Layout : www.paprika-annecy.com
Printed in Malta

CONTENTS

Acknowledgements.....	vii
Abbreviations.....	viii
1. BACKGROUND.....	1
2. WHO POLICY RECOMMENDATION FOR SEASONAL MALARIA CHEMOPREVENTION.....	3
3. SEASONAL MALARIA CHEMOPREVENTION.....	7
3.1 What it is.....	7
3.2 When to implement it.....	7
3.3 Choice of sulfadoxine–pyrimethamine plus amodiaquine.....	8
3.4 Areas suitable for implementation.....	8
3.5 Drug resistance.....	8
3.6 Safety.....	8
3.7 Delivery.....	9
3.8 Importance of adherence to the 3-day regimen.....	9
3.9 Likely cost.....	9
4. NATIONAL ADOPTION OF SEASONAL MALARIA CHEMOPREVENTION.....	11
4.1 Steps in adopting the policy.....	11
4.2 Updating the national malaria control policy.....	12
5. PLANNING IMPLEMENTATION OF SEASONAL MALARIA CHEMOPREVENTION.....	13
5.1 Situation analysis.....	13
5.2 Delivery system.....	13
5.2.1 Community-based approach.....	14
5.2.2 Facility-based system.....	15
5.3 Preparing a plan.....	15
5.3.1 List of key activities.....	15
5.3.2 Estimation of requirement for drugs.....	15
5.3.3 Training staff.....	16
5.3.4 Transport and supply chain management.....	17
5.3.5 Supervision.....	18
5.3.6 Advocacy for community and social mobilization and behavioural change communication.....	18
5.3.7 Administration.....	19
5.4 Activities at various levels.....	22
5.4.1 National malaria control programme.....	22
5.4.2 Regional level.....	22
5.4.3 District level.....	23
5.4.4 Peripheral health centre level.....	23
5.4.5 Community level.....	24
5.5 Reporting.....	25
6. MONITORING AND EVALUATION.....	27
6.1 Performance framework.....	27
6.1.1 Potential indicators.....	27
6.1.2 Baseline data and annual targets.....	28
6.1.3 Data sources and collection methods.....	28
6.1.4 Frequency of reporting.....	28
6.1.5 Person responsible for each indicator.....	29
6.2 Tools for monitoring progress.....	29
6.3 Issues in recording and reporting health information by community health workers.....	29
6.4 Recording drug administration (monitoring and evaluation).....	29
6.5 Estimating coverage.....	30
6.6 Monitoring adverse drug reactions.....	30
6.6.1 Definitions.....	31
6.6.2 Recording and reporting adverse events.....	31
6.6.3 Potential difficulties in reporting adverse events.....	32
6.7 Monitoring the efficacy of sulfadoxine–pyrimethamine plus amodiaquine.....	32
6.7.1 Molecular markers of resistance.....	32
6.7.2 In vitro assays.....	33
6.8 Possible methods for monitoring the effectiveness of seasonal malaria chemoprevention.....	33

ANNEX 1. Distribution of resistance to sulfadoxine–pyrimethamine in sub-Saharan Africa.....	34
ANNEX 2. Sample calendar for community health workers.....	35
ANNEX 3. Sample form for counting treated and untreated children.....	36
ANNEX 4. Sample form for reporting drug accountability by community health workers.....	37
ANNEX 5. Sample supervisory checklist for district health officers monitoring implementation.....	38
ANNEX 6. Sample form for monitoring the performance of community health workers.....	39
ANNEX 7. Sample form for health workers interviewing mothers to assess their knowledge and understanding about seasonal malaria chemoprevention.....	40
ANNEX 8. Sample administration card.....	41
ANNEX 9. Sample form for reporting by health centres and districts.....	42
ANNEX 10. Adverse events reporting form used in a study of the effectiveness of seasonal malaria chemotherapy in Senegal.....	43

ACKNOWLEDGEMENTS

This field guide was produced by the WHO Global Malaria Programme (GMP). GMP gratefully acknowledges the following experts who served in the drafting committee and contributed to the development of this document:

B. Cisse (University Cheikh Anta Diop, Senegal), D. Diallo (Burkina Faso), C.K. Diop (National Malaria Control Programme, Senegal), O. Gaye (University Cheikh Anta Diop, Senegal), M.R. Jibidar (UNICEF, Senegal), E. Lasry (Medecins Sans Frontieres, New York), and P. Milligan (London School of Hygiene and Tropical Medicine, UK).

WHO Staff who contributed to the technical content of this guide: A. Bosman (WHO/GMP), S. Fall (WHO/AFRO), R. Newman (WHO/GMP), P. Olumese (WHO/GMP), F. Pagnoni (WHO/GMP), P. Ringwald (WHO/GMP), M. Warsame (WHO/GMP) and W. Were (WHO/CAH).

The GMP would like to thank the Bill and Melinda Gates Foundation, for providing the financial support to the development and production of this manual.

ABBREVIATIONS

AQ	amodiaquine
SMC	seasonal malaria chemoprevention
SP	sulfadoxine-pyrimethamine
WHO	World Health Organization

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_28119

